Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of “Moderate Buy” from Brokerages

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $31.00.

Several research firms have weighed in on MPLT. Leerink Partners initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target for the company. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $32.00 price target for the company.

Maplight Therapeutics Price Performance

Shares of MPLT stock opened at $17.27 on Monday. Maplight Therapeutics has a twelve month low of $12.24 and a twelve month high of $21.55. The stock’s fifty day moving average price is $17.67. The company has a market cap of $783.59 million and a price-to-earnings ratio of -0.46.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Insider Activity at Maplight Therapeutics

In related news, Director Timothy John Garnett acquired 14,124 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were acquired at an average price of $17.89 per share, with a total value of $252,678.36. Following the completion of the transaction, the director owned 14,124 shares of the company’s stock, valued at $252,678.36. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director George Pavlov purchased 10,658 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were bought at an average price of $17.48 per share, for a total transaction of $186,301.84. Following the acquisition, the director owned 10,658 shares in the company, valued at $186,301.84. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 39,124 shares of company stock worth $693,846 and sold 74,612 shares worth $1,368,065.

Institutional Investors Weigh In On Maplight Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Jain Global LLC acquired a new position in Maplight Therapeutics during the fourth quarter worth $5,756,000. Lazard Asset Management LLC bought a new stake in Maplight Therapeutics during the 4th quarter worth approximately $3,645,000. Baker BROS. Advisors LP acquired a new stake in Maplight Therapeutics during the 4th quarter valued at $6,406,000. 5AM Venture Management LLC acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at $16,687,000. Finally, Burkehill Global Management LP bought a new position in shares of Maplight Therapeutics in the fourth quarter valued at about $1,317,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.